LY4175408 Clinical Trials (2026): 1 Studies for Carcinoma, Non-Small-Cell Lung & Endometrial Neoplasms
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 LY4175408 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Carcinoma, Non-Small-Cell Lung & Endometrial Neoplasms) and 240 total planned enrollment. 1 LY4175408 clinical trial is actively recruiting at 14 U.S. sites across 12 states. Most recent activity: NCT07046923 (Jul 2030).
Where to Participate: All LY4175408 Trial Sites in the U.S. (14 sites across 12 states)
Every actively recruiting LY4175408trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Stanford Medicine Cancer Center | Stanford94305 | NCT07046923 | Map |
| FL | Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute | Orlando32827 | NCT07046923 | Map |
| FL | Florida Cancer Specialists - Sarasota | Sarasota34236 | NCT07046923 | Map |
| IL | The University of Chicago Medical Center (UCMC) | Chicago60637 | NCT07046923 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07046923 | Map |
| MO | Washington University | St Louis63110 | NCT07046923 | Map |
| NJ | John Theurer Cancer Center At Hackensack UMC | Hackensack07601 | NCT07046923 | Map |
| NY | Columbia University | New York10032 | NCT07046923 | Map |
| NY | David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York10065 | NCT07046923 | Map |
| OH | The Ohio State University (OSU) Wexner Medical Center | Columbus43210 | NCT07046923 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT07046923 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT07046923 | Map |
| UT | START Mountain Region | West Valley City84119 | NCT07046923 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT07046923 | Map |
LY4175408 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting LY4175408 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07046923 | A Study of LY4175408 in Participants With Advanced Cancer | P1 | Carcinoma, Non-Small-Cell Lung | 240 | Jul 2025 |
All LY4175408 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07046923 | A Study of LY4175408 in Participants With Advanced Cancer | P1 | recruiting | 240 | Eli Lilly and Company | Jul 2025 |
LY4175408 clinical trials: frequently asked questions
- How many LY4175408 clinical trials are there?
- 1 LY4175408 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are LY4175408 clinical trials recruiting in 2026?
- Yes — 1 LY4175408 trial is actively recruiting in 2026, with 14 U.S. sites across 12 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is LY4175408 being studied for?
- LY4175408 is being studied for Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms, Neoplasm Metastasis, Small Cell Lung Carcinoma, Triple Negative Breast Cancer. The trials are grouped by indication on this page.
- What phase is LY4175408 in?
- LY4175408 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors LY4175408 clinical trials?
- The lead sponsor across the most LY4175408 trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming LY4175408as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: